- Anti-nuclear antibody (ANA) tests, used to detect autoimmune disorders such as lupus and rheumatoid arthritis, are becoming increasingly essential in both clinical and laboratory settings across the Middle East and Africa. This is largely due to rising awareness of autoimmune diseases, improvements in diagnostic infrastructure, and the increasing availability of advanced immunology-based testing platforms
- The rising demand for ANA testing is primarily fueled by an increase in the prevalence of autoimmune conditions, advancements in laboratory technologies, and greater focus on early disease detection and management by regional healthcare authorities
- Saudi Arabia dominated the Middle East and Africa anti-nuclear antibody test market with the largest revenue share of 28.7% in 2024, driven by the country’s extensive healthcare modernization efforts and growing burden of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis
- U.A.E. is projected to be one of the fastest growing countries in the Middle East and Africa anti-nuclear antibody test market during the forecast period (2025–2032). This growth is attributed to increased health awareness, growing demand for early disease diagnosis, and the expansion of private healthcare providers offering autoimmune screening services
- The autoimmune diseases segment dominated the Middle East and Africa anti-nuclear antibody test market with a market share of 82.8% in 2024, owing to the high prevalence of conditions such as lupus, rheumatoid arthritis, and systemic sclerosis in the region, alongside rising awareness and access to diagnostic solutions. The segment continues to grow as healthcare providers prioritize early and accurate detection of autoimmune disorders, supported by increasing availability of advanced testing technologies and expanding clinical guidelines that include ANA testing as a standard diagnostic tool
